Altimmune, Inc. entered into an agreement on November 6, 2025, to offer up to $200 million in common stock through an at-the-market program with Leerink Partners as the sales agent, while terminating a prior agreement for $150 million. This is a significant financial event for the company from an investor perspective, and it has a neutral sentiment.